Horizon Discovery licenses CHOSOURCE platform to TrueBinding for development and commercialization of multiple biotherapeutics
TrueBinding signs multi-product commercial-use license to develop stable, antibody-expressing cell lines using Horizon’s gene-edited CHO GS knockout platform